Potassium Iodide

Summary

Potassium Iodide (CHEMBL1141) is an approved small-molecule radical scavenger (ATC R05CA02); indicated across 8 conditions including anemia and eye disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R05CA02 (+2 more)
• Indications: 8 conditions
• Clinical trials: 9
• Chemistry: 166.0028 Da · IK

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1141
Name	Potassium Iodide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4875
ChEBI	CHEBI:8346
ATC	R05CA02, V03AB21, S01XA04
Molecular formula	IK
Molecular weight	166.0028
InChIKey	NLKNQRATVPKPDG-UHFFFAOYSA-M

SMILES: [K+].[I-]

IUPAC name: potassium iodide

ChEBI definition: A metal iodide salt with a K(+) counterion. It is a scavenger of hydroxyl radicals.

Pharmacological roles (ChEBI): radical scavenger, expectorant.

Other ChEBI roles (chemical / environmental): NMR chemical shift reference compound.

Also known as: Iodine (as potassium iodide), Iodine (as potassium), Iosat, Jodetten depot, Kali iodatum, Kalii iodidum, Kaliumjodid, NSC-77362, Pot iodide ammoniat, Potassium iodide, Thyro-block, Thyrosafe

Patent coverage: 66,270 distinct patent families (164,544 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 164,474 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Carbonic anhydrase 4.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anemia	4	MONDO:0002280	EFO:0004272
eye disorder	4	MONDO:0005328	EFO:0003966
Graves disease	3	MONDO:0005364	EFO:0004237
hyperthyroidism	3	MONDO:0004425	EFO:0009189
lymphoma	2	MONDO:0005062	EFO:0000574
non-Hodgkin lymphoma	2	MONDO:0018908	EFO:0005952
neuroblastoma	1	MONDO:0005072	EFO:0000621

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
Not specified	5
PHASE4	1
PHASE3	1
PHASE2/PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00946296	PHASE4	COMPLETED	Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
NCT00379535	PHASE3	TERMINATED	Preventing Lack of Iodine During Pregnancy
NCT04236830	PHASE2/PHASE3	COMPLETED	Silver Diamine Fluoride/ Potassium Iodide in Indirect Pulp Capping of Young Permanent Molars
NCT03332667	PHASE1	COMPLETED	MIBG With Dinutuximab +/- Vorinostat
NCT02771704	Not specified	COMPLETED	Diamine Silver Fluoride and Potassium Iodide
NCT03649438	Not specified	NO_LONGER_AVAILABLE	131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
NCT04686006	Not specified	COMPLETED	Effective Iodide Therapy for Untreated Patients With Graves’ Hyperthyroidism Avoiding Thionamide Drugs With Many Side Effects
NCT04867291	Not specified	UNKNOWN	Seaweed, the Food Matrix, and Iodine Bioavailability
NCT05628506	Not specified	UNKNOWN	Measurement of Iodolipids in the Thyroid Gland and Other Biological Samples

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).